KRAS and TP53 mutations in colorectal carcinoma.
作者信息
Al-Kuraya Khawla S
出版信息
Saudi J Gastroenterol. 2009 Oct-Dec;15(4):217-9. doi: 10.4103/1319-3767.56087.
Abstract
摘要
相似文献
1
KRAS and TP53 mutations in colorectal carcinoma.结直肠癌中的KRAS和TP53突变
Saudi J Gastroenterol. 2009 Oct-Dec;15(4):217-9. doi: 10.4103/1319-3767.56087.
2
KRAS mutations in primary and metastatic colorectal cancer.原发性和转移性结直肠癌中的KRAS突变
Int J Colorectal Dis. 2013 May;28(5):731-2. doi: 10.1007/s00384-012-1524-5. Epub 2012 Jun 29.
3
TP53 and let-7a micro-RNA regulate K-Ras activity in HCT116 colorectal cancer cells.TP53 和 let-7a 微 RNA 调节 HCT116 结直肠癌细胞中的 K-Ras 活性。
PLoS One. 2013 Aug 1;8(8):e70604. doi: 10.1371/journal.pone.0070604. Print 2013.
4
HSP27 expression in primary colorectal cancers is dependent on mutation of KRAS and PI3K/AKT activation status and is independent of TP53.HSP27 在原发性结直肠癌中的表达依赖于 KRAS 突变和 PI3K/AKT 激活状态，而与 TP53 无关。
Exp Mol Pathol. 2013 Feb;94(1):103-8. doi: 10.1016/j.yexmp.2012.09.001. Epub 2012 Sep 12.
5
[Consensus for KRAS gene mutation detection in colorectal carcinoma].[结直肠癌KRAS基因突变检测的共识]
Zhonghua Bing Li Xue Za Zhi. 2012 Sep;41(9):635-6. doi: 10.3760/cma.j.issn.0529-5807.2012.09.015.
6
The detection of double mutations in KRAS depends on the mutation-detection assay used.KRAS基因双突变的检测取决于所使用的突变检测方法。
Clin Chem. 2011 Jul;57(7):1077-9. doi: 10.1373/clinchem.2010.161190. Epub 2011 Mar 25.
7
Impact of KRAS and BRAF gene mutations on targeted therapies in colorectal cancer.KRAS和BRAF基因突变对结直肠癌靶向治疗的影响。
J Clin Oncol. 2011 Jul 1;29(19):2728-9. doi: 10.1200/JCO.2011.36.1816. Epub 2011 Jun 6.
8
Stromal cells do not share KRAS mutations that the epithelial component harbors in colorectal carcinomas.结直肠癌细胞的间质细胞并不共享上皮成分所具有的 KRAS 突变。
Cancer Lett. 2011 Sep 1;308(1):118-21. doi: 10.1016/j.canlet.2011.04.021. Epub 2011 May 31.
9
Novel multiple, monoallelic KRAS mutations at codon 12 and 13.密码子12和13处新型多个单等位基因KRAS突变
Int J Cancer. 2009 Dec 1;125(11):2744-5. doi: 10.1002/ijc.24635.
10
[Clinical significance and the handling of KRAS testing on metastatic colorectal cancer].[转移性结直肠癌KRAS检测的临床意义及处理]
Nihon Rinsho. 2011 Apr;69 Suppl 3:346-50.
引用本文的文献
1
Unraveling the role of disulfidptosis-related LncRNAs in colon cancer: a prognostic indicator for immunotherapy response, chemotherapy sensitivity, and insights into cell death mechanisms.揭示二硫化物诱导细胞焦亡相关长链非编码RNA在结肠癌中的作用：免疫治疗反应、化疗敏感性的预后指标及对细胞死亡机制的见解
Front Mol Biosci. 2023 Oct 17;10:1254232. doi: 10.3389/fmolb.2023.1254232. eCollection 2023.
2
RNA-Seq-Based Molecular Classification Analyses in Colorectal Cancer and Synchronous Adenoma.基于RNA测序的结直肠癌及同步腺瘤分子分类分析
Cancers (Basel). 2023 Oct 4;15(19):4851. doi: 10.3390/cancers15194851.
3
Effect of KRAS mutations and p53 expression on the postoperative prognosis of patients with colorectal cancer.KRAS 基因突变和 p53 表达对结直肠癌患者术后预后的影响。
Mol Genet Genomic Med. 2022 Jul;10(7):e1905. doi: 10.1002/mgg3.1905. Epub 2022 Jun 10.
4
Transcriptomic Analyses of the Adenoma-Carcinoma Sequence Identify Hallmarks Associated With the Onset of Colorectal Cancer.腺瘤-癌序列的转录组分析确定了与结直肠癌发病相关的特征。
Front Oncol. 2021 Aug 11;11:704531. doi: 10.3389/fonc.2021.704531. eCollection 2021.
5
Chemosensitization of HT29 and HT29-5FU Cell Lines by a Combination of a Multi-Tyrosine Kinase Inhibitor and 5FU Downregulates ABCC1 and Inhibits PIK3CA in Light of Their Importance in Saudi Colorectal Cancer.多靶点酪氨酸激酶抑制剂联合 5FU 增敏 HT29 和 HT29-5FU 细胞系，下调 ABCC1 并抑制 PI3KCA，鉴于其在沙特结直肠癌中的重要性。
Molecules. 2021 Jan 11;26(2):334. doi: 10.3390/molecules26020334.
6
Colorectal cancer in Saudi Arabia as the proof-of-principle model for implementing strategies of predictive, preventive, and personalized medicine in healthcare.沙特阿拉伯的结直肠癌作为在医疗保健中实施预测、预防和个性化医疗策略的原理验证模型。
EPMA J. 2019 Aug 31;11(1):119-131. doi: 10.1007/s13167-019-00186-x. eCollection 2020 Mar.
7
The Correlation of Gene Expression and Immunoexpression in Colorectal Adenocarcinoma.结直肠癌中基因表达与免疫表达的相关性
Open Access Maced J Med Sci. 2019 Jun 30;7(12):1940-1945. doi: 10.3889/oamjms.2019.549.
8
SOX9 Stem-Cell Factor: Clinical and Functional Relevance in Cancer.SOX9干细胞因子：在癌症中的临床及功能相关性
J Oncol. 2019 Apr 1;2019:6754040. doi: 10.1155/2019/6754040. eCollection 2019.
9
Inducible Intestine-Specific Expression of kras Triggers Intestinal Tumorigenesis In Transgenic Zebrafish.诱导型肠道特异性表达 Kras 触发转基因斑马鱼的肠道肿瘤发生。
Neoplasia. 2018 Dec;20(12):1187-1197. doi: 10.1016/j.neo.2018.10.002. Epub 2018 Nov 1.
10
Mutations of p53 and K-ras correlate TF expression in human colorectal carcinomas: TF downregulation as a marker of poor prognosis.p53 和 K-ras 突变与人类结直肠癌中的 TF 表达相关：TF 下调可作为预后不良的标志物。
Int J Colorectal Dis. 2011 May;26(5):593-601. doi: 10.1007/s00384-011-1164-1. Epub 2011 Mar 15.
本文引用的文献
1
Molecular gate keepers succumb to gene aberrations in colorectal cancer in Kashmiri population, revealing a high incidence area.在克什米尔人群的结直肠癌中，分子门控因子因基因异常而失活，揭示了一个高发地区。
Saudi J Gastroenterol. 2009 Oct-Dec;15(4):244-52. doi: 10.4103/1319-3767.56102.
2
PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.结直肠癌中的PIK3CA突变与对表皮生长因子受体（EGFR）靶向单克隆抗体的临床耐药性相关。
Cancer Res. 2009 Mar 1;69(5):1851-7. doi: 10.1158/0008-5472.CAN-08-2466. Epub 2009 Feb 17.
3
Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers.在一项基于人群的结肠癌系列研究中，RAS-MAPK、PI(3)K（磷脂酰肌醇-3-羟基激酶）信号网络中的突变与较差的生存率相关。
Int J Cancer. 2008 May 15;122(10):2255-9. doi: 10.1002/ijc.23388.
4
Clinicopathological analysis of colorectal cancers with PIK3CA mutations in Middle Eastern population.中东人群中携带PIK3CA突变的结直肠癌的临床病理分析
Oncogene. 2008 Jun 5;27(25):3539-45. doi: 10.1038/sj.onc.1211013. Epub 2008 Jan 14.
5
Colorectal cancer: a multipathway disease.结直肠癌：一种多途径疾病。
Crit Rev Oncog. 2006 Dec;12(3-4):273-87. doi: 10.1615/critrevoncog.v12.i3-4.50.
6
HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer.结直肠癌中HER2、TOP2A、CCND1、EGFR和C-MYC癌基因扩增
J Clin Pathol. 2007 Jul;60(7):768-72. doi: 10.1136/jcp.2006.038281. Epub 2006 Aug 1.
7
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.KRAS 突变状态可预测结直肠癌患者对西妥昔单抗治疗的反应。
Cancer Res. 2006 Apr 15;66(8):3992-5. doi: 10.1158/0008-5472.CAN-06-0191.
8
Beyond 5-fluorouracil: new horizons in systemic therapy for advanced colorectal cancer.超越5-氟尿嘧啶：晚期结直肠癌全身治疗的新视野
Expert Opin Investig Drugs. 2005 Jun;14(6):607-28. doi: 10.1517/13543784.14.6.607.
9
Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer.贝伐单抗联合氟尿嘧啶和亚叶酸钙：一线转移性结直肠癌的有效治疗方案。
J Clin Oncol. 2005 May 20;23(15):3502-8. doi: 10.1200/JCO.2005.10.017.
10
p53 mutation profile of squamous cell carcinomas of the esophagus in Kashmir (India): a high-incidence area.印度克什米尔地区：一个食管癌高发地区食管鳞状细胞癌的p53突变谱
Int J Cancer. 2005 Aug 10;116(1):62-8. doi: 10.1002/ijc.21002.
Zotero 插件